UNSPSC 51413903: Cinepaxadil

This classification denotes a vasodilating agent with the molecular formula C29H36N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E052L8N506, chemically known as alpha-(((8-acetyl-1,4-benzodioxan-5-yl)oxy)methyl)-4-(3,4,5-trimethoxycinnamoyl)-1-piperazineethanol but generally known as cinepaxadil, which bears US NIH Compound Identifier 6436099. European Medicines Agency schedules Cinepaxadil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06290MIG.

UNSPSC 51413903 Cinepaxadil is a Commodity code capturing pharmaceutical products procured by state and local health agencies, emergency services, and cooperative purchasing alliances. State and local governments use this code to source medications and pharmaceutical supplies for public health programs, emergency medical services, and multi-jurisdictional pharmacy benefit initiatives. Recent solicitations show purchasing of advanced life support medications, generic pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing vehicles.

Issuing bodies span city fire-rescue departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited advanced life support medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue, requiring 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with nine-month minimum expiration dates and one-year contract terms; this solicitation carried a $40,000 estimated value and a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with contract terms beginning July 1, 2026 and requiring cGMP certification, DSCSA compliance, and relationships with authorized wholesalers. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Recent activity spans Florida, Texas, Minnesota, and Oregon, with procurement emphasis on cost management, product compliance, and multi-jurisdictional distribution networks.